Table 1.
Comparison of general information and demographic characteristics
| Parameter | No adverse reactions (n=113) | Adverse reactions (n=47) | t/χ2 | P |
|---|---|---|---|---|
| Age (years) | 58.52 ± 5.24 | 59.81 ± 4.75 | 1.523 | 0.131 |
| Gender (M/F) | 69 (61.06%)/44 (38.94%) | 20 (42.55%)/27 (57.45%) | 3.888 | 0.049 |
| Body mass index (kg/m2) | 22.99 ± 3.06 | 24.09 ± 3.15 | 2.020 | 0.047 |
| Smoking history | 33 (29.2%) | 12 (25.53%) | 0.077 | 0.781 |
| Drinking history | 19 (16.81%) | 9 (19.15%) | 0.016 | 0.9 |
| Comorbidities (%) | ||||
| Hypertension | 12 (10.62%) | 5 (10.64%) | 0 | 1 |
| Diabetes | 18 (15.93%) | 9 (19.15%) | 0.069 | 0.792 |
| ECOG performance status | 0 | 1 | ||
| 0 | 37 (32.74%) | 15 (31.91%) | ||
| 1 | 76 (67.26%) | 32 (68.09%) | ||
| Family history of cancer | 25 (22.12%) | 9 (19.15%) | 0.043 | 0.836 |
| History of CNS involvement | 34 (30.09%) | 16 (34.04%) | 0.093 | 0.761 |
| Liver metastasis | 19 (16.81%) | 9 (19.15%) | 0.016 | 0.9 |
| Histology | 0 | 1 | ||
| Squamous | 2 (1.77%) | 1 (2.13%) | ||
| Non-squamous | 111 (98.23%) | 46 (97.87%) | ||
| Disease stage | 0 | 1 | ||
| Locally advanced and unresectable | 5 (4.42%) | 2 (4.26%) | ||
| Metastatic | 108 (95.58%) | 45 (95.74%) |
Note: ECOG: Eastern Cooperative Oncology Group.